Cellectar CFO granted 92,000 stock options

Kolean Chad J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kolean Chad J reported acquisition or exercise transactions in this Form 4 filing.

Cellectar Biosciences CFO Chad J. Kolean received a grant of 92,000 stock options to buy common shares at $3.14 per share. The options were contingently granted on May 28, 2026, under Cellectar's amended 2021 Stock Incentive Plan and became effective after stockholders approved the plan on July 7, 2026.

The award vests over three years from May 28, 2026, with one-third vesting on the first anniversary and the remaining two-thirds vesting in 24 equal monthly installments thereafter. Following this grant, Kolean holds 92,000 stock options directly under this award.

Insider Trade Summary

Grant/Award: 92,000 shares

Grant/Award 1 txn

Insider Kolean Chad J

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	92,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 92,000 contracts (Direct)

Footnotes (2)

1. F1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
2. F2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026.

Key Figures

Option grant size: 92,000 options Exercise price: $3.14 per share Options held after grant: 92,000 options +3 more

6 metrics

Option grant size 92,000 options Grant to CFO Chad J. Kolean

Exercise price $3.14 per share Stock option exercise price

Options held after grant 92,000 options Total from this award following transaction

Option expiration May 28, 2036 Option expiration date

Grant start date May 28, 2026 Reference date for vesting schedule

Shareholder approval date July 7, 2026 Plan approval making contingent grant effective

Key Terms

2021 Stock Incentive Plan, Annual Meeting of Stockholders, stock option (right to buy), vest, +1 more

5 terms

2021 Stock Incentive Plan financial

"subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan"

Annual Meeting of Stockholders regulatory

"at Cellectar's 2026 Annual Meeting of Stockholders"

stock option (right to buy) financial

"security_title: Stock option (right to buy)"

vest financial

"This option shall vest over a period of three years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

common stock financial

"underlying_security_title: Common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) report for its CFO?

Cellectar Biosciences reported a compensation-related grant of 92,000 stock options to CFO Chad J. Kolean. The options allow him to buy common stock at $3.14 per share, contingent on prior shareholder approval of the amended 2021 Stock Incentive Plan.

What is the exercise price and size of the Cellectar (CLRB) CFO option grant?

CFO Chad J. Kolean received stock options for 92,000 shares at an exercise price of $3.14 per share. These options relate to Cellectar’s common stock and were granted as part of the company’s amended 2021 Stock Incentive Plan.

How do the Cellectar (CLRB) CFO stock options vest over time?

The 92,000 stock options granted to Cellectar’s CFO vest over three years from May 28, 2026. One-third vests on the first anniversary, and the remaining two-thirds vest in 24 equal monthly installments starting on that first anniversary date.

What shareholder approval was required for the Cellectar (CLRB) CFO option grant?

The option grant was contingent on stockholder approval of Cellectar’s amended 2021 Stock Incentive Plan at the 2026 Annual Meeting. That approval was obtained on July 7, 2026, making the 92,000-option award effective for the CFO.

Is the Cellectar (CLRB) CFO option grant an open-market share purchase?

No, the CFO’s 92,000-share option grant is a compensation award, not an open-market purchase. It provides the right to buy common stock at $3.14 per share, subject to the vesting schedule over three years from May 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kolean Chad J

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$3.14	07/07/2026(1)		A		92,000		(2)	05/28/2036	Common stock	92,000	$0	92,000	D

Explanation of Responses:

1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.

2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026.

	/s/ Chad Kolean	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)